Skip to main content
SpringerLink
Log in

Literature review and commentary

  • Commentary
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111(9): 692–698.

    Google Scholar 

  2. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356(9223): 26–30.

    Google Scholar 

  3. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60(3): 1154–1163.

    Google Scholar 

  4. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30(10): 2205–2211.

    Google Scholar 

  5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343(3): 180–184.

    Google Scholar 

References

  1. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347(11): 781–789.

    Google Scholar 

  2. Jani AB, Hellman S. Early prostate cancer: clinical decisionmaking. Lancet 2003; 361(9362): 1045–1053.

    Google Scholar 

  3. Ansari MS, Gupta NP, Hemal AK. Chemoprevention of carcinoma prostate: a review. Int Urol Nephrol 2002; 34(2): 207–214.

    Google Scholar 

  4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280(11): 975–980.

    Google Scholar 

References

  1. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994; 150(6): 899–913.

    Google Scholar 

  2. Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a metaanalysis. CMAJ 2003; 169(6): 557–564.

    Google Scholar 

  3. Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993; 56(3): 539–555.

    Google Scholar 

  4. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003; 58(4): 331–353.

    Google Scholar 

References

  1. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. The Lancet 1999; 354: 359–364.

    Google Scholar 

  2. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. The Lancet 1998; 352: 1252–1256.

    Google Scholar 

  3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. The Lancet 2000; 355: 253–259.

  4. Bargman JM, Thorpe KE, Churchill D. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158–2162.

    Google Scholar 

  5. Moist LM, Port FK, Orzol SM, Young EW, Ostbye TR, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE. Predictors of Loss of Residual Renal Function among New Dialysis Patients. J Am Soc Nephrol 2000; 11: 556–564.

    Google Scholar 

  6. Dyadyk A, Bagriy A, Lebed I, Yarovaya N, Schukina E, Taradin G. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997; 12: 945–951.

    Google Scholar 

References

  1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154–2169.

    Google Scholar 

  2. Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work. Can Med Assoc J 2003; 169: 30–31.

    Google Scholar 

  3. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the national registry of myocardial infarction 3. Circulation 2001; 103: 38–44.

    Google Scholar 

  4. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, ta-blockers, and lipidlowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999; 159: 561–567.

    Google Scholar 

  5. Salomon L, Levu S, Deray G, Launay-Vacher V, Brucker G, Ravaud P. Assessing residents' prescribing behavior in renal impairment. Int J Qual Health Care 2003; 15: 235–240.

    Google Scholar 

  6. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations*. The Lancet 1999; 354: 1457–1463.

    Google Scholar 

References

  1. Black DM et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85.1: 4118–4124.

    Google Scholar 

  2. Coco M, Feingold R, Faugere MC, Durkin P, Negolescu O, Wang G, Malluche H. Use of pamidronate in ESRD patients with calcium phosphorous product prohibitive for vitamin D replacement. J Am Soc Neph 2003; 14 [Abstracts Issue]: 470A.

    Google Scholar 

  3. Cosman F et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13.6: 1051–1055.

    Google Scholar 

  4. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289.19 (2003): 2525–2533.

    Google Scholar 

  5. Infante M, Hernandez G, Rojas E, Fuenmayor N, Dominguez J, Suniaga O, Weisnger JR, Bellorin-Font E. The spectrum of renal bone disease in chronic kidney disease (CKD) stages 3 to 5: Possible contribution of osteoporosis. J Am Soc Neph 2003; 14 [Abstracts Issue]: 471A.

    Google Scholar 

  6. Lindsay R et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350.9077: 550–555.

    Google Scholar 

  7. Neer RM et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344.19: 1434–1441.

    Google Scholar 

  8. Orwoll ES et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18.1: 9–17.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Canada

    S.V. Jassal & S.M.H. Alibhai

  2. University Department Clinical Nephrology, University of British Columbia, Canada

    C.E. Stigant & W.L. Cook

Authors
  1. S.V. Jassal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.E. Stigant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W.L. Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S.M.H. Alibhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jassal, S., Stigant, C., Cook, W. et al. Literature review and commentary. Int Urol Nephrol 35, 581–593 (2003). https://doi.org/10.1023/B:UROL.0000025660.34891.ea

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:UROL.0000025660.34891.ea

Search

Navigation